Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Inhibitex: Following the tried and true

While every fledgling company hopes to follow in the footsteps of its successful forebears, Inhibitex Inc. hopes to actually mimic the footsteps of its role models.

In developing its MSCRAMMs to treat bacterial and fungal infections, the company's model is MedImmune Inc. - starting with a polyclonal antibody for a given indication and subsequently developing a monoclonal antibody to replace the original product. In the marketing arena, Inhibitex will position its products as

Read the full 728 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers